

Common vasopressors and inotropes

The table outlines clinical indications, associated receptors, physiology, dosing, titration rates, and adverse effects of various vasopressors and inotropes.*

Vasopressor	Clinical indications	Receptor	Physiologic effects	Dosing	Starting dose	Dose titration increment	Rate of titration	Adverse effects
Norepinephrine	<ul style="list-style-type: none"> Acute hypotension Cardiogenic shock Septic shock (after initial fluid bolus) 	<ul style="list-style-type: none"> α1 β1 	<ul style="list-style-type: none"> Vasoconstriction Increased CO 	<ul style="list-style-type: none"> 0.1-3.3 mcg/kg/min Titrate to effect Weight-based dosing 	0.01 mcg/kg/min	0.1-0.15 mcg/kg/min	1-15 min	<ul style="list-style-type: none"> Arrhythmias Tissue necrosis Ischemia Reflex bradycardia
Epinephrine	<ul style="list-style-type: none"> Septic shock Anaphylactic shock Cardiac arrest 	<ul style="list-style-type: none"> α1 β1 β2 	<ul style="list-style-type: none"> Vasoconstriction Vasodilation (β2) Increased CO Decreased SVR 	<ul style="list-style-type: none"> 0.1-0.5 mcg/kg/min Titrate to effect Weight-based dosing 	0.1 mcg/kg/min	0.1-0.5 mcg/kg/min	1-15 min	<ul style="list-style-type: none"> Arrhythmias Cardiac ischemia Tissue necrosis Insulin secretion inhibition
Phenylephrine	<ul style="list-style-type: none"> Septic shock Cardiogenic shock Vasodilatory shock 	α1	Vasoconstriction	<ul style="list-style-type: none"> 40-200 mcg/min (0.5-2 mcg/kg/min) Titrate to effect 	40 mcg/min	0.01-0.05 mcg/kg/min	1-15 min	<ul style="list-style-type: none"> Reflex bradycardia Tissue necrosis Ischemia
Vasopressin	<ul style="list-style-type: none"> Diabetes insipidus Esophageal variceal bleeding Vasodilatory shock Septic shock Anaphylactic shock Used as adjunct with other pressors to decrease high-dose side effects 	Vasopressin (V1)	Increased SVR	0.01-0.07 units/min	Initial: ≤0.03 units/min	Usually not titrated	30-60 min	<ul style="list-style-type: none"> Arrhythmias Cardiac ischemia Mesentery ischemia
Inotrope	Clinical indications	Receptor	Physiologic effects	Dosing	Starting dose	Dose titration increment	Rate of titration	Adverse effects
Dobutamine	First drug of choice for <ul style="list-style-type: none"> Cardiogenic shock Sepsis-induced myocardial dysfunction 	<ul style="list-style-type: none"> β1 β2 	<ul style="list-style-type: none"> Increased CO Vasodilation Hypotension 	2-20 mcg/kg/min	2 mcg/kg/min 2.5 mcg/kg/min in more severe cardiac decompensation	2.5 mcg/kg/min	5-15 min	<ul style="list-style-type: none"> Hypotension Arrhythmias Hypokalemia
Dopamine	<ul style="list-style-type: none"> Cardiogenic shock Septic shock 	<ul style="list-style-type: none"> Dopamine receptors β1 α1 	Effects vary by dosage: 1-2 mcg/kg/min <ul style="list-style-type: none"> Selective renal vasodilation 5-10 mcg/kg/min <ul style="list-style-type: none"> Increased CO Increased SV > 10 mcg/kg/min <ul style="list-style-type: none"> Vasoconstriction Increased SVR 	2-20 mcg/kg/min	2-5 mcg/kg/min	1-5 mcg/kg/min	1-15 min	<ul style="list-style-type: none"> Arrhythmias Cardiac ischemia Extravasation and tissue necrosis
Milrinone	<ul style="list-style-type: none"> Inodilator Improve perfusion Bridge to transplant 	<ul style="list-style-type: none"> PDE-I (Type 3) Nonadrenergic mechanism 	<ul style="list-style-type: none"> Increased SvO_2 Increased CVP Increased SVR 	0.125-0.5 mcg/kg/min	0.375 mcg/kg/min	0.125 mcg/kg/min	15-30 minutes	<ul style="list-style-type: none"> Hypotension Arrhythmias Nausea Vomiting

CO = cardiac output, CVP = central venous pressure, SvO_2 = mixed venous oxygen saturation, SVR = systemic vascular resistance

*Refer to full prescribing information before administration.